

DECEMBER MEDIA COVERAGE

INDEX

S. No	Date	Publication	Edition	Headline
Wires				
1	22-Dec-23	PTI	Online	Pharma industry eyes sustained growth, more collaborative efforts in New Year
Financials				
2	8-Dec-23	Financial Express	Online	Govt needs to take some concrete measures to demonstrate that they value intellectual property: Anil Matai, Director-General, OPPI
3	13-Dec-23	The Economic Times	Print	Drug launches, new permissions should be made public, say pharma MNCs
4	13-Dec-23	The Economic Times	Online	Drug launches, new permissions should be made public, say pharma MNCs
5	22-Dec-23	Business Standard	Online	Pharma industry optimistic, expects more collaborative efforts in New Year
6	22-Dec-23	Business Standard (Hindi)	Online	New Year 2024: Pharma industry expected to grow continuously in the new year
7	29-Dec-23	Business Standard	Online	Pharma lobby bats for drug approvals in India to align with global markets
8	29-Dec-23	The Economic Times	Online	India's pharma lobby bats for drug approvals in line with global markets
Mainlines				
9	22-Dec-23	Deccan Herald	Online	Pharma industry eyes sustained growth, more collaborative efforts in New Year
Online and Trade				
10	4-Dec-23	PharmaBoardroom	Online	Indian Pharma Betting on Innovation Over Next 25 Years, say OPPI Summit Speakers
11	7-Dec-23	News18	Online	New Drug Launches See 4-Year Lag in India vs US and EU: Lobby of Foreign Drugmakers to DCGI

12	12-Dec-23	The Print	Online	Tax doctors on research grants by drugmakers, says govt panel reviewing pharma marketing practices
13	13-Dec-23	Prmament	Online	OPPI's Asawari Sathaye decodes what ASCI's influencer guidelines mean for responsible health communication
14	15-Dec-23	ET HealthWorld	Online	DMDC Bill will align India's regulatory system with global best regulatory practices'
15	18-Dec-23	BW Businessworld	Online	Navigating The Future Key Trends Shaping The Pharmaceutical Landscape In 2024
16	19-Dec-23	Express Pharma	Online	As we look ahead to 2024, pharma sector is poised for sustained growth and innovation
17	21-Dec-23	Scrip	Online	OPPI's Matai On Winds Of Policy Change In India, Quality Oversight
18	22-Dec-23	ET HealthWorld	Online	Pharma Medtech Sector: Pharma industry eyes sustained growth, more collaborative efforts in New Year
19	22-Dec-23	The Print	Online	Pharmaceutical industry expected to grow steadily in the new year
20	22-Dec-23	Dev Discourse	Online	Pharma industry eyes sustained growth, more collaborative efforts in New Year
21	22-Dec-23	NDTV Profit	Online	Pharma Industry Eyes Sustained Growth, More Collaborative Efforts In 2024
22	22-Dec-23	NDTV	Online	Pharma industry eyes sustained growth, more collaborative efforts in New Year
23	22-Dec-23	Live Hindustan	Online	Pharma sector will take off in the new year on the basis of affordable generic medicines
24	22-Dec-23	Prabhat Khabar	Online	Medicine industry in 2024 going to reach record high but will have to face many challenge mdn
25	22-Dec-23	The Hawk	Online	Pharma industry eyes sustained growth, more collaborative efforts in New Year

26	22-Dec-23	Newsdrum	Online	Pharma industry eyes sustained growth, more collaborative efforts in New Year
27	31-Dec-23	News18	Online	Upgrade Quality or Risk Shutdowns': How India's New DCGI is Rebuilding 'Pharmacy of the World'

WIRES

Publication	PTI
Date	22-Dec-23
Edition	Online
Headline	Pharma industry eyes sustained growth, more collaborative efforts in New Year

PRESS TRUST OF INDIA

Pharma industry eyes sustained growth, more collaborative efforts in New Year

Updated: Dec 22 2023 11:08AM

By Munish Shekhavat

New Delhi, Dec 22 (PTI) The domestic pharmaceutical industry expects another year of sustained growth in 2024 amid various challenges, including maintaining quality standards, while moving from volume to value leadership.

The industry, known for catering to global markets with affordable generic products, expects to further leverage collaborative efforts, invest in Research & Development (R&D) and uphold quality standards to meet the evolving healthcare needs.

"The convergence of policy thrust, and India's entrepreneurial vigour will propel the sector's growth and ensure a consistent supply of quality-assured affordable medicines for patients, both in India and globally," Indian Pharmaceutical Alliance (IPA) Secretary General Sudarshan Jain told PTI.

FINANCIALS

Publication	Financial Express
Date	03-Dec-23
Edition	Online
Headline	Govt needs to take some concrete measures to demonstrate that they value intellectual property: Anil Matai, Director-General, OPPI

Govt needs to take some concrete measures to demonstrate that they value intellectual property: Anil Matai, Director-General, OPPI

One major challenge is to provide quality access because we need our products to reach much deeper to tier 2 and tier three markets as well, Matai told Financial Express.com.

Written by [Sushmita Panda](#)

December 8, 2023 07:00 IST



Anil Matai, Director-General, OPPI.

The pharmaceutical industry continues to play a pivotal role in the global market. For decades, India has been known as the 'Pharmacy of the World'. The industry represents over 20 percent of the global generics supply by volume and caters to approximately 60 percent of the global demand for vaccines.

Publication	The Economic Times
Date	13-Dec-23
Edition	Print
Headline	Drug launches, new permissions should be made public, say pharma MNCs



ISTOCK

Drug Launches, Permissions Should be Made Public, Say Pharma MNCs

Association's request, if implemented, could hurt local pharma cos

Teena Thacker

New Delhi: The Organisation of Pharmaceutical Producers of India (OPPI), which represents prominent multinational pharma companies, has urged India's drug controller to make new launches and new drug permissions of Indian pharma companies open to the public, a move that could help them track potential infringers thereby



Move may help global cos track likely infringers thereby obtaining timely interim injunction

obtaining timely interim injunction from the courts. The proposal, if implemented, could hurt Indian pharma companies. In a recent meeting held by the drug controller on global clinical trials, the OPPI sought from the government a notification system through the drug regulatory authority's digital portal-SUGAM. It has asked for linking of the portal at centre and state levels and making public the non-commercial information of the filed/pending applications and approvals granted, it said. An executive with a lobby group representing Indian pharma companies said, asking to notify all the applications on the portal for all to see will help the multinational companies.


teena.thacker@timesgroup.com

Publication	The Economic Times
Date	13-Dec-23
Edition	Online
Headline	Drug launches, new permissions should be made public, say pharma MNCs

Drug launches, new permissions should be made public, say pharma MNCs

Synopsis

In a recent meeting held by the drug controller on global clinical trials, the OPPI sought from the government a notification system through the drug regulatory authority's digital portal-SUGAM. It has asked for linking of the SUGAM Portal at Centre and state levels and, then, making public the non-commercial information in respect of the filed/pending applications and the approvals granted, it said.



Representational image

The Organisation of Pharmaceutical Producers of India (OPPI), which represents prominent multinational pharma companies, has urged India's drug controller to make new launches and new drug permissions of [Indian pharma companies](#) open to the public, a move that could help them track potential infringers thereby obtaining

timely interim injunction from the courts. The proposal, if implemented, could hurt Indian pharma companies.

In a recent meeting held by the drug controller on global clinical trials, the OPPI sought from the government a notification system through the drug regulatory authority's digital portal-SUGAM. It has asked for linking of the SUGAM Portal at Centre and state levels and, then, making public the non-commercial information in respect of the filed/pending applications and the approvals granted, it said.

Publication	Business Standard
Date	22-Dec-23
Edition	Online
Headline	Pharma industry optimistic, expects more collaborative efforts in New Year

Business Standard
Friday, January 05, 2024 | 09:57 AM IST EN | Hindi

[Home](#) / [Industry](#) / [News](#) / Pharma industry optimistic, expects more collaborative efforts in New Year

Pharma industry optimistic, expects more collaborative efforts in New Year

The domestic pharmaceutical industry expects another year of sustained growth in 2024 amid various challenges, including maintaining quality standards, while moving from volume to value leadership



Representative Image

Press Trust of India | New Delhi

4 min read Last Updated : Dec 22 2023 | 11:32 AM IST

The domestic pharmaceutical industry expects another year of sustained growth in 2024 amid various challenges, including maintaining quality standards, while moving from volume to value leadership.

Publication	Business Standard (Hindi)
Date	22-Dec-23
Edition	Online
Headline	New Year 2024: Pharma industry expected to grow continuously in the new year

बिज़नेस स्टैंडर्ड

New Year 2024: फार्मा इंडस्ट्री को नए साल में निरंतर ग्रोथ की उम्मीद

ग्लेनमार्क फार्मास्यूटिकल्स के चेयरमैन ने कहा कि भारतीय दवा उद्योग ने पिछले 5 वर्षों में निर्यात में सालाना आधार पर 8% की वृद्धि से वैश्विक स्तर पर महत्वपूर्ण प्रगति की है।

पीटी भाषा

घरेलू दवा उद्योग को बढ़ते हुए गुणवत्ता मानकों को बनाए रखने सहित विभिन्न चुनौतियों के बीच 2024 में निरंतर वृद्धि की उम्मीद है। किफायती जेनैरिक उत्पादों के साथ वैश्विक बाजारों की जरूरतों को पूरा करने के लिए पहचाना जाने वाला उद्योग, बढ़ती स्वास्थ्य देखभाल आवश्यकताओं को पूरा करने के लिए सहयोगात्मक प्रयासों को आगे बढ़ाने, अनुसंधान एवं विकास (आरएंडडी) में निवेश करने और गुणवत्ता मानकों को बनाए रखने की उम्मीद कर रहा है।

इंडियन फार्मास्यूटिकल एलायंस (आईपीए) के महासचिव सुदर्शन जैन ने 'पीटीआई-भाषा' से कहा, "नीतिगत सुधार और भारत की उद्यमशीलता शक्ति का अभिस्रण इस क्षेत्र की वृद्धि को बढ़ावा देगा। साथ ही यह भारत और वैश्विक स्तर पर मरीजों के लिए उचित गुणवत्ता वाली एवं सस्ती दवाओं की निरंतर आपूर्ति भी सुनिश्चित करेगा। आईपीए में शीर्ष घरेलू दवा कंपनियां सन फार्मा, डॉ. रेड्डीज लैबोरेटरीज, अरबिंदो फार्मा, सिप्ला, ल्यूपिन और ग्लेनमार्क शामिल हैं।"

जैन ने कहा कि इस साल सरकार ने फार्मा मेडटेक सेक्टर (पीआरआईपी) में अनुसंधान तथा नवाचार को बढ़ावा देने, राष्ट्रीय दवा नीति पर दृष्टिकोण पत्र जैसी विभिन्न नीतिगत पहलों की घोषणा की और जी20 शिखर सम्मेलन के दौरान 'वन हेल्थ' पर भी जोर दिया। 'ऑर्गनाइजेशन ऑफ फार्मास्यूटिकल प्रोड्यूसर्स ऑफ इंडिया' (ओपीपीआई) के महानिदेशक अनिल मटाई ने कहा कि दवा क्षेत्र 2024 में निरंतर वृद्धि और नवाचार के लिए तैयार है।

उन्होंने कहा, "अगले साल हम सरकार और दवा उद्योग के बीच निरंतर साझेदारी की उम्मीद करते हैं। इससे प्रगति होगी, नवाचार को बढ़ावा मिलेगा और अंततः एक स्वस्थ व अधिक मजबूत समाज विकसित करने में मदद मिलेगी।"

Publication	Business Standard
Date	29-Dec-23
Edition	Online
Headline	Pharma lobby bats for drug approvals in India to align with global markets

Pharma lobby bats for drug approvals in India to align with global markets

Launching a new drug in India takes up to four years longer than in markets such as the United States and the European Union, said the pharma lobby



BS Web Team | [New Delhi](#)

2 min read Last Updated : Dec 29 2023 | 12:21 PM IST




Listen to This Article

To hasten the launch of new medicines in India, the Organisation of Pharmaceutical Producers of India (OPPI), which represents key multinational pharmaceutical companies, has urged the drug controller to enable parallel approval of drugs in sync with global markets, reported *The Economic Times (ET)*.

According to the OPPI, launching a new drug in India takes up to four years longer than in markets such as the United States and the European Union (EU). This has an impact on the introduction of innovative and significant products in India, it said.


Publication	The Economic Times
Date	29-Dec-23
Edition	Online
Headline	India's pharma lobby bats for drug approvals in line with global markets

India's pharma lobby bats for drug approvals in line with global markets

Synopsis

According to the OPPI, launching a new drug in India is delayed by up to four years, compared to markets like the US and the European Union. This affects the launch of innovative and significant products in India. The lobby represents pharma giants including Novartis, Roche, AstraZeneca, Sanofi and Merck. The group blames the delay on complex clinical trial regulations.



Representative Image

New Delhi: The [Organisation of Pharmaceutical Producers of India \(OPPI\)](#), which represents prominent [multinational pharma companies](#), has urged the drug controller to enable parallel approval of drugs in sync with global markets, to expedite the launch of new medicines in India.

According to the OPPI, launching a [new drug in India](#) is delayed by up to four years, compared to markets like the US and the European Union. This affects the launch of innovative and significant products in India.

The lobby represents pharma giants including [Novartis](#), [Roche](#), [AstraZeneca](#), Sanofi and Merck.

The group blames the delay on complex clinical trial regulations.

"OPPI envisions a transformative approach to [drug approval processes](#), advocating for regulations that enable parallel filing of marketing approval applications in sync with major global markets," the pharma lobby group told ET in a statement.

MAINLINES

Publication	Deccan Herald
Date	22-Dec-23
Edition	Online
Headline	Pharma industry eyes sustained growth, more collaborative efforts in New Year

Pharma industry eyes sustained growth, more collaborative efforts in New Year

The industry, known for catering to global markets with affordable generic products, expects to further leverage collaborative efforts, invest in Research & Development (R&D) and uphold quality standards to meet the evolving healthcare needs.

 PTI

Last Updated 22 December 2023, 12:39 IST

Follow Us



The Organisation of Pharmaceutical Producers of India's (OPPI) Director General Anil Matai said the pharmaceutical sector is poised for sustained growth and innovation in 2024.

Credit: iStock Photo

New Delhi: The domestic pharmaceutical industry expects another year of sustained growth in 2024 amid various challenges, including maintaining quality standards, while moving from volume to value leadership.

ONLINE AND TRADE

Publication	PharmaBoardroom
Date	4-Dec-23
Edition	Online
Headline	Indian Pharma Betting on Innovation Over Next 25 Years, say OPPI Summit Speakers

Indian Pharma Betting on Innovation Over Next 25 Years, say OPPI Summit Speakers



 Patrick Burton on 04.12.2023

 SAVE      SHARE

Tags: [India](#), [OPPI](#), [Association](#), [Pfizer](#), [Investment](#), [Innovation](#), [Access](#)

India's pharma industry has big dreams. At the recent Annual Summit of Organisation of Pharmaceutical Producers of India (OPPI) the nation's policymakers, academicians, industry leaders, innovators, and scientists gathered to set out their industry's trajectory up to 2047. Based on discussions at the conference and a comprehensive new OPPI report, co-authored with global strategy consultancy EY Parthenon, OPPI aims to make India "the innovation powerhouse of the world," an integral part of global pharma supply chains, and achieve sustainable and equitable healthcare access for all.

Bold Ambitions

The summit, attended in person by PharmaBoardroom, was permeated by a mood of confidence. Industry and government stakeholders alike seemed keen to work together to propel India up the innovation value chain and secure greater access to cutting-edge medicines at home.

Publication	News18
Date	7-Dec-23
Edition	Online
Headline	New Drug Launches See 4-Year Lag in India vs US and EU: Lobby of Foreign Drugmakers to DCGI

New Drug Launches See 4-Year Lag in India vs US and EU: Lobby of Foreign Drugmakers to DCGI

• Reported By: [Himani Chandra](#) • Edited By: [Nitya Thirumalai](#) • [News18.com](#) • Last Updated: DECEMBER 07, 2023, 09:46 IST • [New Delhi, India](#)



Be it for oncology, rare diseases, or other innovations, OPPI said there is delayed access to innovative medicines for Indian patients and global organizations are hesitant to include India in phase III studies. (Representative image/Getty Images)

Launching new drugs in India takes up to a four-year delay compared to the US or the European Union, primarily due to complex clinical trial regulations, the lobby of foreign drugmakers told India's apex drug regulator, News18 has learnt.

On November 24, the Drug Controller General of India (DCGI) invited domestic and foreign players to discuss the challenges around global clinical trials.

The Organisation of Pharmaceutical Producers of India (OPPI), the lobby representing top pharma giants in India, including Novartis, Roche, Astra Zeneca, Sanofi, Merck and others, told DCGI in its presentation that there is a lack of ecosystem supporting innovation.

The presentation, accessed by News18, said "regulatory capacity building is not in line with newer advances in clinical research".

Publication	The Print
Date	12-Dec-23
Edition	Online
Headline	Tax doctors on research grants by drugmakers, says govt panel reviewing pharma marketing practices

Tax doctors on research grants by drugmakers, says govt panel reviewing pharma marketing practices

Five-member panel suggests doctors can't be given brand reminders exceeding Rs 1,000 each, Uniform Code of Pharmaceutical Marketing Practices to remain voluntary, but strengthened.



A pharmacy in New Delhi | Representational image | ThePrint

Text Size: [A-](#) [A+](#)

New Delhi: A high-level government panel set up to review the Uniform Code of Pharmaceutical Marketing Practices (UCPMP) in India has recommended that pharma associations should disclose the money they spend per doctor in conferences. As an addition to the existing UCPMP, it has also suggested that doctors cannot be given brand reminders, where the value exceeds Rs 1,000 per item, ThePrint has learnt.

Publication	PRmoment India
Date	13-Dec-23
Edition	Online
Headline	OPPI's Asawari Sathaye decodes what ASCI's influencer guidelines mean for responsible health communication

OPPI's Asawari Sathaye decodes what ASCI's influencer guidelines mean for responsible health communication

🕒 13th December 2023 🗒 Opinion

In the digital age, social media influencers wield remarkable power in shaping public opinions and trends. This influence, while valuable, must be wielded responsibly, especially when it comes to health-related information.

Recognising this, the Advertising Standards Council of India (ASCI) took a significant step by mandating that influencers must disclose their relevant qualifications, such as a medical degree or be a certified nurse, nutritionist, dietician, physiotherapist, psychologist etc., depending on the specific advice being given. Additionally, all advertisements shared by influencers must be labelled as such.

This move underscores the importance of accurate health information and is a commendable effort to maintain the integrity of health-related content on social media platforms.



Asawari
Sathaye, OPPI

Publication	ET Healthworld
Date	15-Dec-23
Edition	Online
Headline	'DMDC Bill will align India's regulatory system with global best regulatory practices'

'DMDC Bill will align India's regulatory system with global best regulatory practices'

The Drugs, Medical Devices, and Cosmetics Bill, 2023 if made into a law, is expected to benefit patients in terms of expeditious access to new, safe, and quality therapies, informed Dr Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI)



Prathiba Raju • ETHealthWorld
Updated On Dec 15, 2023 at 01:45 PM IST



New Delhi: The Drugs, Medical Devices, and Cosmetics Bill, 2023, which is expected to be introduced during the ongoing session of Parliament, aims to regulate and supervise the import, production, distribution, and sale of drugs, medical devices, and

cosmetics, and ensure standards in quality, safety, efficacy, and performance. If made into a law, is expected to benefit patients in terms of expeditious access to new, safe, and quality therapies, informed Dr Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI)

Publication	BW Businessworld
Date	18-Dec-23
Edition	Online
Headline	Navigating The Future Key Trends Shaping The Pharmaceutical Landscape In 2024



HOMEHEALTHCARE PROVIDERSTECHNOLOGYINSURANCEFINANCEREGULATORYPE

SUBSCRIBE TO PRINT

Navigating The Future: Key Trends Shaping The Pharmaceutical Landscape In 2024



The pharmaceutical sector gears up for a transformative year with trends focusing on personalised medicine, digital health integration, sustainability, AI innovations, emerging markets, regulatory agility, data privacy, and global health crisis preparedness, promising groundbreaking advancements and patient-centric care

Publication	Express Pharma
Date	19-Dec-23
Edition	Online
Headline	As we look ahead to 2024, pharma sector is poised for sustained growth and innovation

As we look ahead to 2024, pharma sector is poised for sustained growth and innovation

By EP News Bureau — On Dec 19, 2023

LATEST UPDATES GUEST BLOGS



Share    

242 0

Anil Matal, Director General, Organisation of Pharmaceutical Producers of India (OPPI) shares that in 2024, we anticipate a continued partnership between the government and the pharma industry, driving advancements, fostering innovation, and ultimately contributing to a healthier and more resilient society

In 2023, the pharma sector witnessed a dynamic landscape marked by robust government initiatives and a renewed industry focus on innovation, collaboration, and R&D. The Government of India played a pivotal role in shaping the industry's trajectory, emphasising key aspects that set the tone for the year. The government's emphasis on recognising and incentivising innovative approaches underscored the industry's commitment to advancing medical solutions. Collaborative efforts among industry players, research institutions, and academia thrived, contributing to an environment of shared knowledge and expertise. A paramount focus on quality will undoubtedly play a significant role in ensuring the safety and efficacy of pharma products. Announcement of stringent measures and encouragement for adherence to international quality standards underscored the commitment to delivering reliable and high-quality healthcare solutions on the part of the government as well as the sector as a whole.

Publication	Scrip
Date	21-Dec-23
Edition	Online
Headline	OPPI's Matai On Winds Of Policy Change In India, Quality Oversight



CITELINE COMMERCIAL

21 Dec 2023 | Interviews

OPPI's Matai On Winds Of Policy Change In India, Quality Oversight

by Anju Ghangurde

Incoming director general of the Organisation of Pharmaceutical Producers of India, Anil Matai, talks to *Scrip* about the evolving policy and regulatory landscape in India in areas such as R&D and quality. Stricter adherence to ethical marketing practices and transparency in interactions between pharma and physicians could be key focus areas in the coming year, he adds.

The Organization of Pharmaceutical Producers of India (OPPI)'s new director general, Anil Matai, sees a distinct shift in the "tone" at the helm of the Indian drug regulatory apparatus – it's one that is "talking science, research and innovation".

"We are clearly seeing that directionally we're moving there, and that message is percolating down [the ranks] as well. We're getting positive signals that things are changing," said Matai in a wide-ranging interview with *Scrip*. The OPPI essentially represents the interests of foreign firms in India.

While the bureaucracy has its task cut out, Matai also highlighted the Indian government's intent around backing R&D and a clear acknowledgement that "it comes at some cost".

A case in point is perhaps India's recent approach paper on the Draft National Pharmaceuticals Policy 2023, which, among a range of objectives, talks about ensuring that essential medicines remain affordable to all, but also seeks to "strike a balance that encourages fair pricing without stifling innovation".

Publication	ET Healthworld
Date	22-Dec-23
Edition	Online
Headline	Pharma Medtech Sector: Pharma industry eyes sustained growth, more collaborative efforts in New Year

Pharma industry eyes sustained growth, more collaborative efforts in New Year

The pharma industry, known for catering to global markets with affordable generic products, expects to further leverage collaborative efforts, invest in Research and development (R&D), and uphold quality standards to meet the evolving healthcare needs, inform experts.



PTI

Updated On Dec 22, 2023 at 06:37 PM IST



New Delhi : The domestic pharmaceutical industry expects another year of sustained growth in 2024 amid various challenges, including maintaining quality standards, while moving from volume to value leadership. The industry, known for catering

to global markets with affordable generic products, expects to further leverage collaborative efforts, invest in Research & Development (R&D) and uphold quality standards to meet the evolving healthcare needs.

"The convergence of policy thrust, and India's entrepreneurial vigour will propel the sector's growth and ensure a consistent supply of quality-assured affordable medicines for patients, both in India and globally," said [Sudarshan Jain](#), Secretary General, Indian Pharmaceutical Alliance (IPA)

Publication	The Print
Date	22-Dec-23
Edition	Online
Headline	Pharmaceutical industry expected to grow steadily in the new year

दवा उद्योग के नए साल में निरंतर वृद्धि करने की उम्मीद

भाषा 22 December, 2023 11:48 am IST

'ऑर्गेनाइजेशन ऑफ फार्मास्युटिकल प्रोड्यूसर्स ऑफ इंडिया' (ओपीपीआई) के महानिदेशक अनिल मटाई ने कहा कि दवा क्षेत्र 2024 में निरंतर वृद्धि और नवाचार के लिए तैयार है।

उन्होंने कहा, " अगले साल हम सरकार और दवा उद्योग के बीच निरंतर साझेदारी की उम्मीद करते हैं। इससे प्रगति होगी, नवाचार को बढ़ावा मिलेगा और अंततः एक स्वस्थ व अधिक मजबूत समाज विकसित करने में मदद मिलेगी।"

ग्लेनमार्क फार्मास्युटिकल्स के चेयरमैन एवं प्रबंध निदेशक ग्लेन सल्दान्हा ने कहा कि भारतीय दवा उद्योग ने पिछले पांच वर्षों में निर्यात में सालाना आधार पर आठ प्रतिशत की वृद्धि से वैश्विक स्तर पर महत्वपूर्ण प्रगति की है।

उन्होंने कहा, " मूल्य श्रृंखला में आगे बढ़ने की हमारी रणनीति के तहत नवाचार और जटिल जेनेरिक विकसित करने पर जोर देने के साथ हम दुनिया भर में मरीजों की बढ़ती स्वास्थ्य देखभाल आवश्यकताओं को पूरा करने की दिशा में काम करना जारी रखेंगे।"

डॉ. रेड्डीज लैबोरेटरीज के प्रवक्ता ने कहा कि भारतीय दवा क्षेत्र का लक्ष्य 2030 तक 120-130 अरब अमेरिकी डॉलर और 2047 तक 350-400 अरब अमेरिकी डॉलर तक बढ़ने का है।

Publication	Dev Discourse
Date	22-Dec-23
Edition	Online
Headline	Pharma industry eyes sustained growth, more collaborative efforts in New Year

Pharma industry eyes sustained growth, more collaborative efforts in New Year

PTI | New Delhi | Updated: 22-12-2023 11:40 IST | Created: 22-12-2023 11:12 IST



Representative image image Credit: ANI

Country: [India](#)

SHARE [f](#) [t](#) [in](#) [e](#)

The domestic pharmaceutical industry expects another year of sustained growth in 2024 amid various challenges, including maintaining quality standards, while moving from volume to value leadership.

ADVERTISEMENT

Publication	NDTV Profit
Date	22-Dec-23
Edition	Online
Headline	Pharma Industry Eyes Sustained Growth, More Collaborative Efforts In 2024

Pharma Industry Eyes Sustained Growth, More Collaborative Efforts In 2024

The industry expects to further leverage collaborative efforts, invest in R&D and uphold quality standards to meet the evolving healthcare needs



The domestic pharmaceutical industry expects another year of sustained growth in 2024 amid various challenges, including maintaining quality standards, while moving from volume to value leadership.

The industry, known for catering to global markets with affordable generic products, expects to further leverage collaborative efforts, invest in Research & Development and uphold quality standards to meet the evolving healthcare needs.

"The convergence of policy thrust, and India's entrepreneurial vigour will propel the sector's growth and ensure a consistent supply of quality-assured affordable medicines for patients, both in India and globally," Indian Pharmaceutical Alliance, Secretary General Sudarshan Jain told PTI.

IPA comprises top domestic pharmaceutical companies, including Sun Pharma, Dr Reddy's Laboratories, Aurobindo Pharma, Cipla, Lupin and Glenmark.

Jain said that this year, the government announced various policy initiatives like the Promotion of Research and Innovation in Pharma MedTech Sector, approach paper on National Pharma Policy and displayed thrust on 'One Health' during the G20 Summit.

Publication	NDTV
Date	22-Dec-23
Edition	Online
Headline	Pharma industry eyes sustained growth, more collaborative efforts in New Year

नए साल में विभिन्न चुनौतियों के बीच दवा उद्योग के निरंतर वृद्धि करने की उम्मीद

डॉ. रेड्डीज लैबोरेटरीज के प्रवक्ता ने कहा कि भारतीय दवा क्षेत्र का लक्ष्य 2030 तक 120-130 अरब अमेरिकी डॉलर और 2047 तक 350-400 अरब अमेरिकी डॉलर तक बढ़ने का है।

Reported by भाषा Updated: 22 दिसम्बर, 2023 2:30 PM



नई दिल्ली: घरेलू दवा उद्योग को बढ़ते हुए गुणवत्ता मानकों को बनाए रखने सहित विभिन्न चुनौतियों के बीच 2024 में निरंतर वृद्धि की उम्मीद है.किफायती जेनेरिक उत्पादों के साथ वैश्विक बाजारों की जरूरतों को पूरा करने के लिए पहचाना जाने वाला उद्योग, बढ़ती स्वास्थ्य देखभाल आवश्यकताओं को पूरा करने के लिए सहयोगात्मक प्रयासों को आगे बढ़ाने, अनुसंधान एवं विकास (आरएंडडी) में निवेश करने और गुणवत्ता मानकों को बनाए रखने की उम्मीद कर रहा है.

Publication	Live Hindustan
Date	22-Dec-23
Edition	Online
Headline	Pharma sector will take off in the new year on the basis of affordable generic medicines

किफायती जेनेरिक दवाओं के दम पर फार्मा सेक्टर नए साल में भरेगा उड़ान

Pharma Sector Outlook 2024: डॉ. रेड्डीज लैबोरेटरीज के प्रवक्ता ने कहा कि भारतीय फार्मा सेक्टर का लक्ष्य 2030 तक 120-130 अरब अमेरिकी डॉलर और 2047 तक 350-400 अरब अमेरिकी डॉलर तक बढ़ने का है।



Dinraj Madheshia • एजेंसी, नई दिल्ली

Fri, 22 Dec 2023 12:29 PM



हमें फॉलो करें



Publication	Prabhat Khabar
Date	22-Dec-23
Edition	Online
Headline	Medicine industry in 2024 going to reach record high but will have to face many challenge mdn

Medicine Industry in 2024: रिकॉर्ड ऊंचाई पर जाने वाला है मेडिसिन उद्योग, मगर इस चुनौती का करना होगा सामना

घरेलू दवा उद्योग को बढ़ते हुए गुणवत्ता मानकों को बनाए रखने सहित विभिन्न चुनौतियों के बीच 2024 में निरंतर वृद्धि की उम्मीद है.

By Agency | Updated Date Fri, Dec 22, 2023, 2:35 PM IST



Medicine Industry in 2024 | File

Medicine Industry in 2024: कोविड काल के बाद से भारत में दवा उद्योग एक नयी दिशा में आगे बढ़ रही है. 2023 में दवा उद्योग ने काफी अच्छा प्रदर्शन किया. हालांकि, घरेलू दवा उद्योग को बढ़ते हुए गुणवत्ता मानकों को बनाए रखने सहित विभिन्न चुनौतियों के बीच 2024 में निरंतर वृद्धि की उम्मीद है. किफायती जेनरिक उत्पादों के साथ वैश्विक बाजारों की जरूरतों को पूरा करने के लिए पहचाना जाने वाला उद्योग, बढ़ती स्वास्थ्य देखभाल आवश्यकताओं को पूरा करने के लिए सहयोगात्मक प्रयासों को आगे बढ़ाने, अनुसंधान एवं विकास (आरएंडडी) में निवेश करने और गुणवत्ता मानकों को बनाए रखने की उम्मीद कर रहा है. इंडियन फार्मास्युटिकल एलायंस (आईपीए) के महासचिव सुदर्शन जैन ने कहा कि नीतिगत सुधार और भारत की उद्यमशीलता शक्ति का अभिसरण इस क्षेत्र की वृद्धि को बढ़ावा देगा. साथ ही यह भारत और वैश्विक स्तर पर मरीजों के लिए उचित गुणवत्ता वाली एवं सस्ती दवाओं की निरंतर आपूर्ति भी सुनिश्चित करेगा. आईपीए में शीर्ष घरेलू दवा कंपनियां सन फार्मा, डॉ. रेड्डीज लैबोरेटरीज, अरबिंदो फार्मा, सिप्ला, ल्यूपिन और ग्लेनमार्क शामिल हैं.

Publication	The Hawk
Date	22-Dec-23
Edition	Online
Headline	Pharma industry eyes sustained growth, more collaborative efforts in New Year

Pharma industry eyes sustained growth, more collaborative efforts in New Year

Anticipated Growth and Innovations in India's Pharmaceutical Industry for 2024 - A comprehensive overview of policy initiatives, R&D investments, and quality standards shaping the industry's trajectory amid evolving healthcare needs.



New Delhi: The domestic pharmaceutical industry expects another year of sustained growth in 2024 amid various challenges, including maintaining quality standards, while moving from volume to value leadership.

The industry, known for catering to global markets with affordable generic products, expects to further leverage collaborative efforts, invest in Research & Development (R&D) and uphold quality standards to meet the evolving healthcare needs.

Publication	Newsdrum
Date	22-Dec-23
Edition	Online
Headline	Pharma industry eyes sustained growth, more collaborative efforts in New Year

Pharma industry eyes sustained growth, more collaborative efforts in New Year



NewsDrum Desk

22 Dec 2023

[Follow Us](#)



New Delhi, Dec 22 (PTI) The domestic pharmaceutical industry expects another year of sustained growth in 2024 amid various challenges, including maintaining quality standards, while moving from volume to value leadership.

Matai said the dedicated benches will play a crucial role in adjudication of complex scientific and technical issues involved in pharmaceutical patents, fostering a climate conducive to innovation, and ensuring fair competition within the industry.


Addressing the complexity of clinical trial regulations, the industry is hopeful of regulatory support that enables parallel launches in India, he noted.

Streamlining these processes will not only expedite market entry but also contribute to a more patient-centric approach, ensuring timely access to innovative and life-changing medicines, he said.

Publication	News18
Date	31-Dec-23
Edition	Online
Headline	Upgrade Quality or Risk Shutdowns': How India's New DCGI is Rebuilding 'Pharmacy of the World'

Newsmaker | 'Upgrade Quality or Risk Shutdowns': How India's New DCGI is Rebuilding 'Pharmacy of the World'

• Reported By: [Himani Chandna](#) • Edited By: [Apoorva Misra](#) • [News18.com](#) • Last Updated: DECEMBER 31, 2023, 14:29 IST • [New Delhi, India](#)



**YEAR-END
2023, in
review**

India's pharmaceutical industry has undergone a comprehensive regulatory overhaul spearheaded by the nation's apex health regulatory agency and its chief, the Drug Controller General of India (DCGI), amid quality concerns raised by global regulators.

Throughout the year, DCGI Rajeev Singh Raghuvanshi made headlines for his several moves, ranging from aggressive raids on pharmaceutical units nationwide, revoking production licenses, introducing Schedule M, guiding micro and medium-sized pharmaceutical companies, to delivering a resolute message to pharma units to either upgrade or risk shutdowns.

Trouble started in October 2022 when India was accused of exporting contaminated medicine to The Gambia, which led to the deaths of several children. However, this was just the beginning.